First Trust Direct Indexing L.P. Sells 900 Shares of Bruker Corporation
July 20, 2023
☀️Trending News
First Trust Direct Indexing L.P. has recently sold 900 shares of Bruker Corporation ($NASDAQ:BRKR), a global scientific instruments and solutions company with a focus on providing life science, material science and analytical technologies for a range of industries. Bruker Corporation is a leader in the development and production of high-performance devices and systems for life science research, clinical research, biopharmaceutical analysis and diagnostics. Its products are used in a variety of fields including organic chemistry, proteomics, drug discovery, clinical chemistry, microbiology and industrial applications. The company also designs and manufactures tools for a wide range of other industries including medical device manufacturing, semiconductor manufacturing and environmental testing. The partnership is focused on developing innovative molecular imaging systems.
With this move, investors have been bullish on the stock’s prospects going forward. First Trust Direct Indexing L.P.’s sale of 900 shares of Bruker Corporation provides a good potential entry point for those looking to buy the stock for the long-term. With the company’s continued focus on innovation and its promising partnerships, now could be the perfect time to invest in Bruker Corporation.
Price History
At the opening of the market, the stock price of BRUKER CORPORATION was $73.8, and it closed at $75.8, a 2.7% increase from the prior closing price. This trading activity reflects an overall market trend of increased investment in the company, as investors are showing a strong interest in its products and services. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.62k | 311.5 | 12.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 284.1 | -258 | -228.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.76k | 2.55k | 7.58 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 21.4% | 17.4% |
| FCF Margin | ROE | ROA |
| 5.7% | 24.6% | 7.6% |
Analysis
At GoodWhale, we have conducted a comprehensive analysis of BRUKER CORPORATION, and based on our Risk Rating, we have determined that the company is a medium risk investment from financial and business aspects. We identified two risk warnings in their balance sheet and cashflow statement, so be sure to take that into account when assessing your portfolio. To get detailed information on BRUKER CORPORATION’s wellbeing, register on goodwhale.com and access our reports, ratings, and insights. With GoodWhale, you can make informed decisions about any company or sector and ensure that your investments are secure. More…
Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
BRUKER CORPORATION is a leading provider of scientific instruments and solutions. First Trust Direct Indexing L.P. recently sold 900 shares of BRUKER stock, which may have been influenced by recent market conditions and/or the company’s current valuation. Investors should pay close attention to the company’s financials, revenue growth, cash flow, and other key metrics to assess the stock’s potential. It is important to consider BRUKER’s competitive landscape, industry trends, and the company’s competitive advantages to get a better sense of the stock’s potential.
Furthermore, investors should take into account risks associated with the stock including management strength, debt levels, dividend policy, and macroeconomic factors. Analyzing this data can help investors formulate an informed investment decision.
Related Posts
Recent Posts
